Stereotactic radiation therapy in non–small cell lung cancer (NSCLC) patients with operable Stage I disease resulted in a 76% overall survival at three years. These findings were recently presented at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Lung cancer is a major cause of death worldwide, with over one million deaths per year. Non–small cell lung cancer (NSCLC) is the most common type of lung cancer. Early-stage NSCLC is most often treated with surgical resection with or without the addition of radiation therapy and/or chemotherapy. In some cases, patients may not be able to undergo surgery to remove their cancer due to underlying conditions such as emphysema or heart disease. Treatment of early-stage NSCLC patients who are unable to undergo surgery may include radiation therapy or observation. Strategies to improve treatment for this group of patients include stereotactic radiation therapy.
Stereotactic radiation therapy involves the very precise delivery of a large dose of radiation to a tumor while sparing normal tissue. Results from a study recently published in the Journal of the American Medical Association indicate that patients with early-stage NSCLC who were medically unable to undergo surgery to remove their cancer had a 55.8% overall survival at three years following stereotactic body radiation therapy. Researchers recently conducted a study to evaluate whether or not early-stage NSCLC patients eligible for surgery might also benefit from stereotactic radiation therapy.
In this Phase II Japanese study, researchers evaluated stereotactic radiation therapy among 65 patients with Stage I NSCLC that was considered operable. At three years, overall survival was 76% and progression-free survival was 54.5%. Side effects tended to be mild.
The researchers concluded that stereotactic radiation therapy is effective with few side effects and may provide Stage I NSCLC patients with an alternative to surgery, especially elderly patients.
 Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070-1076.
Copyright © 2016 CancerConsultants. All Rights Reserved.
[ doxazosin 1mg pills $128.00 | zantac 150mg pills $115.00 | zenegra 100mg pills $72.00 | actos 15mg pills $103.00 | cefixime 100mg pills $269.00 | olmesartan 40mg pills $294.00 | cefixime 50mg pills $139.00 | tinidazole 300mg pills $140.00 | prednisone 20mg pills $174.00 | flomax 0.2mg pills $138.00 | adalat 20mg pills $150.00 | adalat 10mg pills $118.00 | norvasc 5mg pills $174.00 | levitra 60mg pills $349.00 | professional viagra 100mg pills 270 $324.00 | clopidogrel 75mg pills $231.00 | geodon 80mg pills $135.00 | coversyl 8mg pills $182.00 | acyclovir 200mg pills $111.00 | best way to use cialis | enalapril 10mg pills $270.00 | risperdal 2mg pills $88.00 | glucophage 500mg pills $172.00 | tizanidine 2mg pills $321.00 | book buy guest sign viagra | lamisil 250mg pills $189.00 | ed trial packs cialis oral jelly 20mg + viagra oral jelly 100mg $131.00 | atarax 25mg pills $132.00 | kamagra 50mg pills $154.00 | nexium 20mg pills $170.00 | benicar 40mg pills $251.00 | fluoxetine 60mg pills $128.00 | prescription cialis | chloroquine 500mg pills $198.00 | uses of viagra | female pharmaceutical viagra | retin-a 0.025% cream in 20g tube $64.00 | zetia 10mg pills $252.00 | bactrim 480mg pills $102.00 | relafen 750mg pills $138.00 | cipro 750mg pills 270 $189.00 | adhd atomoxetine 40mg pills $175.00 | generic cialis canadian | provanol 40mg pills $147.00 | methotrexate 2.5mg pills $97.00 | requip 0.5mg pills $229.00 | super viagra | womens viagra | adhd atomoxetine 10mg pills $194.00 | tricor 200mg pills $259.00 | minomycin 50mg pills $378.00 | v-gel 30ml tube $217.00 | diabecon 60 tablet bottle $157.00 | viagra and alcohol ]
© Nebraska Hematology-Oncology | Web Design & Development by UNANIMOUS